News

In the company’s ongoing Phase I/II clinical trial, a one-time administration of Epodure, producing and delivering the low dose of 18-25IU/kg/day of the protein erythropoietin (EPO), was sufficient

‘ON’ time represents periods when Parkinson’s patients experience their best level of motor functioning. According to the company, the two safinamide treatment groups of the study (receiving either

In India the company plans to begin marketing the oral herpes device pursuant to the exclusive worldwide distribution rights it acquired from NeuroMed, as previously announced. The company

Under the agreement, eResearchTechnology (ERT) and Integrium will deliver a combined solution to meet the increased demand for centralized cardiac safety and ambulatory blood pressure monitoring (ABPM) services

Jetstream is a peripheral atherectomy catheter designed to remove all kinds of artery-clogging plaque in the lower limbs of patients. According to Pathway, Jetstream G2 is capable of

The CAP trial was a prospective, randomized, double-blind, 26-week study designed to examine the effects of low-dose versus high-dose Lipitor on hsCRP levels in men and women under

The merger creates a late-stage, publicly traded specialty pharmaceutical company engaged in the development and commercialization of proprietary products that address important therapeutic needs in the fields of

Transgenomic, a biotechnology company, and Power3 Medical Products, a bio-medical company, have signed a definitive collaboration and exclusive licensing agreement for the rights to Power3 Medical’s neurodegenerative biomarkers.

Reported revenues increased 1% to a record $2.65 billion in the fourth quarter of 2008, against $2.62 billion in the 2007 quarter. The quarterly revenue growth reflects the